Valneva edges up on 'well oriented' FY, 'solid' forecasts

Valneva SE

20/03/2025 08:27

** Shares in Valneva VLS.PA edge up 3%, paring earlier gains of as much as 7.3%, boosted by improving FY results

** The French vaccine maker reports FY gross margin on product sales of 50.6%, with net loss reduced to 12.2 mln euros  ($13.27 mln)

** Van Lanschot Kempen applauds continued improvement in gross margin, strong sales of Japanese encephalitis vaccine Ixiaro, and an encouraging launch of chikungunya vaccine Ixchiq

** Portzamparc says results are "well oriented", while the outlook is "solid"

** Valneva expects to reduce its cash burn by 50% in 2025, while total revenues should reach 180-190 mln euros

($1 = 0.9196 euros)

 (Reporting by Hugo Lhomedet)

 ((Hugo.Lhomedet@thomsonreuters.com;))